Physician profile
Robert P Baughman
NPI 1417912783
$639,821.23
in general payments reported to CMS, 2019-2025
14 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $43K · 2021: $127K · 2022: $163K · 2023: $114K · 2024: $94K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $220K · Travel and Lodging: $19K · Food and Beverage: $2,663 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $219,730.00 |
| Travel and Lodging | $19,159.63 |
| Food and Beverage | $2,662.67 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $518,502.94 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $56,392.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,431.71 | 2020-2022 | |
| United Therapeutics Corporation | $18,271.63 | 2020-2022 | |
| Actelion Pharmaceuticals, LTD | $8,699.71 | 2019 | |
| Abbvie INC. | $4,512.50 | 2021-2022 | |
| Csl Behring | $2,771.28 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $103.42 | 2019 | |
| Janssen Research & Development, LLC | $66.71 | 2019 | |
| Merck Sharp & Dohme LLC | $51.08 | 2024 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baughman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.